Prognostic Implications and Efficacy of Catheter Ablation by Atrial Fibrillation Type

Hiroshi Miyama1, Seiji Takatsuki1, Nobuhiro Ikemura1,2

  • 1Department of Cardiology Keio University School of Medicine Tokyo Japan.

Insights

Persistent atrial fibrillation (PersAF) is linked to worse outcomes than paroxysmal atrial fibrillation (PAF). Catheter ablation (CA) may reduce adverse events for both AF types, but careful consideration of AF type is crucial.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Clinical Research

Background:

  • Catheter ablation (CA) is standard for paroxysmal atrial fibrillation (PAF) but selectively used for persistent atrial fibrillation (PersAF).
  • Differences in prognosis and the impact of CA between PAF and PersAF are not fully understood.

Purpose of the Study:

  • To compare clinical outcomes and quality of life between patients with PAF and PersAF.
  • To evaluate the effectiveness of CA in both PAF and PersAF patients.

Main Methods:

  • Analysis of a multicenter atrial fibrillation (AF) cohort study with 2788 patients categorized as PAF (≤7 days) or PersAF (>7 days).
  • Comparison of a composite outcome (death, heart failure hospitalization, stroke, bleeding) and Atrial Fibrillation Effect on Quality-of-life (AFEQoL) scores over 2 years.
  • Propensity score matching to compare CA versus medication in both AF types.

Main Results:

  • PersAF patients had higher composite event rates (12.8% vs. 7.2%) and poorer AFEQoL improvement than PAF patients.
  • PersAF independently predicted adverse outcomes (aHR=1.35) and was linked to worse AFEQoL.
  • CA significantly reduced adverse events in PAF (OR=0.31) and showed a similar trend in PersAF.

Conclusions:

  • Persistent atrial fibrillation is a significant risk factor for adverse clinical outcomes and diminished quality of life.
  • Catheter ablation is associated with reduced adverse events, particularly in PAF, suggesting its potential benefit in PersAF requires careful patient selection.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
40
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
56
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
38
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14